en.Wedoany.com Reported - FundaMental Pharma GmbH announced the appointment of Dr. Hans Eriksson as Chief Medical Officer, where he will be fully responsible for the clinical strategy of the company's oral dual-acting NMDAR modulator, FMP374. This drug targets the NMDAR/TRPM4 complex disruption combined with NMDAR antagonism, aiming to provide rapid and sustained relief for patients with treatment-resistant depression while avoiding excessive NMDAR pharmacology.
Dr. Eriksson brings over 25 years of clinical development experience in the pharmaceutical and biotechnology sectors, having held positions at AstraZeneca, Lundbeck, Compass Pathways, and HMNC Brain Health. He has been involved in eight late-stage clinical development programs for depression, three of which received approval for the treatment of major depressive disorder. Most recently, he served as Chief Medical Officer at HMNC Brain Health, overseeing the development of the oral extended-release ketamine formulation Ketabon (KET01); prior to that, he was Chief Medical Officer at Compass Pathways, leading the clinical development of the psychedelic therapy psilocybin (COMP360). During his tenure at AstraZeneca and Lundbeck, he served as Global Medical Lead for Seroquel, Seroquel XR, and TC5214, and as Clinical Lead for the co-development of brexpiprazole. Dr. Eriksson holds an MD and a PhD from Lund University, an Executive MBA from the Stockholm School of Economics, and has a clinical background as a consultant psychiatrist.
Dr. Dirk Beher, CEO of FundaMental Pharma, stated that Dr. Eriksson's outstanding track record and direct experience in advancing programs from late-stage development to market are crucial for the company in overcoming the challenges of treatment-resistant depression and advancing its clinical mission.
Dr. Eriksson expressed that FundaMental Pharma's approach has the potential to offer differentiated treatment options for patients with treatment-resistant depression, noting that FMP374 has demonstrated compelling characteristics in preclinical studies. He looks forward to collaborating with the team to prepare for clinical development.
The company's leadership team will attend the BIO International Convention 2026, to be held from June 22 to 25, 2026, in San Diego, USA.
FundaMental Pharma GmbH is a preclinical-stage biopharmaceutical company headquartered in Germany, Heidelberg. Its research is based on the pioneering work of Professor Hilmar Bading and Dr. Jing Yan, published in the journal Science. The company's proprietary dual-acting NMDAR modulators disrupt the NMDAR/TRPM4 complex while exerting potent NMDAR antagonism. The lead compound, FMP374, demonstrates robust antidepressant-like efficacy at low nanomolar unbound drug concentrations, without dissociation-related behaviors, ataxia, or hyperactivity at effective doses. It exhibits oral bioavailability and is ready for IND-enabling studies. The company aims to redefine the treatment paradigm for treatment-resistant depression.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
